Typhoons associated with heavy rainfall events, potentially triggering harmful algal blooms (cyanoHABs) dominated by cyanobacteria in coastal reservoirs. These blooms deteriorate water quality and produce toxins, posing a threat to aquatic ecosystems. However, the ecological mechanisms driving cyanobacteria communities in response to typhoons remain unclear. To address this gap, we investigated a coastal reservoir with high-frequency sampling during two typhoon seasons. We employed comprehensive statistical methods under neutral and evolutionary theories to analyze environmental dynamics and cyanobacterial genus succession. Our findings revealed a significant increase in nutrient loads following typhoons, with concentrations of total nitrogen (TN), total phosphorus (TP), and ammonia-nitrogen (NH-N) rising from 0.4 mg/L to 1.0 mg/L, 0.02 mg/L to 0.63 mg/L, and 0.03 mg/L to 0.26 mg/L, respectively. These changes coincided with fluctuations in other physicochemical parameters under changing hydrometeorological conditions. Despite significant environmental disturbances, the cyanobacterial community exhibited a remarkable recovery within 15-25 days following the typhoons. This recovery progressed through four distinct successional phases, with a notable shift in community composition from Raphidiopsis and Pseudoanabaena to Aphanocapsa, subsequently replaced by Raphidiopsis and Microcystis, before reverting to the pre-typhoon community structure. During the entire successional phase, the availability of TN and the TN/TP ratio played a dominant role, as indicated by PLS-PM analysis (total effects = -0.6; p < 0.05). Pre-typhoon, environmental factors primarily influenced community structure (54 %) based on modified stochasticity ratio. However, following the typhoons, stochastic fluctuations took precedence (71 %-91 %). The rapid recovery of cyanobacterial communities and the shift in driving mechanisms from deterministic to stochastic processes underscore the complex ecological responses to typhoon events. This study provides essential insights for biodiversity preservation and ecosystem restoration, emphasizing the need to consider both stochastic and deterministic processes in ecological management strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.watres.2024.122480 | DOI Listing |
PLoS One
January 2025
Department of Surgery, Asian Liver Center, Stanford University School of Medicine, Stanford, California, United States of America.
Patients with chronic hepatitis B infection (CHB) have an increased risk for death from liver cirrhosis and hepatocellular carcinoma (HCC). In the United States, only an estimated 37% of adults with chronic hepatitis B diagnosis without cirrhosis receive monitoring with at least an annual alanine transaminase (ALT) and hepatitis B deoxyribonucleic acid (DNA), and an estimated 59% receive antiviral treatment when they develop active hepatitis or cirrhosis. A Markov model was used to calculate the costs, health impact and cost-effectiveness of increased monitoring of adults with HBeAg negative inactive or HBeAg positive immune tolerant CHB who have no cirrhosis or significant fibrosis and are not recommended by the current American Association for the Study of Liver Diseases (AASLD) clinical practice guidelines to receive antiviral treatment, and to assess whether the addition of HCC surveillance would be cost-effective.
View Article and Find Full Text PDFMicrosc Res Tech
January 2025
Dipartimento di Fisica, Università di Genova, Genova, Italy.
MINFLUX nanoscopy relies on the localization of single fluorophores with expected ~ 2 nm precision in 3D mapping, roughly one order of magnitude better than standard stimulated emission depletion microscopy or stochastic optical reconstruction microscopy. This "brilliant" technique takes advantage of specialized localization principles and algorithms that require only dim fluorescence signals with a minimum flux of photons; hence the name follows. With this level of performance, MINFLUX imaging and tracking should allow for the routine study of biological processes down to the molecular scale, revealing previously unresolved details in cell structures, such as the organization of calcium channels in muscle cells or the clustering of receptors in synapses.
View Article and Find Full Text PDFBMC Public Health
January 2025
Center for Pharmacoeconomics and Outcomes Research, China Pharmaceutical University, Nanjing, 211198, China.
Background: This study assessed the effectiveness and cost-effectiveness of breast cancer screening across rural and urban regions in China's four economic zones.
Methods: Using a decision-analytic Markov model, we evaluated 5,280 scenarios involving different ages and screening technologies. The model followed individuals from birth through 100 yearly cycles in eight settings.
Sci Rep
January 2025
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
This study evaluates the cost-effectiveness of adding durvalumab to chemotherapy, with subsequent maintenance either with olaparib (DOCT) or without olaparib (DCT), versus chemotherapy alone (CT) as a first-line treatment for advanced endometrial cancer (EC) in the United States, stratified by mismatch repair deficiency (dMMR) and proficiency (pMMR). A Markov model based on DUO-E Phase III trial data simulated disease progression and outcomes. Total costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICER) were evaluated.
View Article and Find Full Text PDFBMJ Open
January 2025
Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, People's Republic of China
Objective: To evaluate the cost-effectiveness of polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.
Design: A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). The clinical outcomes were obtained from the POLARIX(NCT03274492), SCHOLAR-1, ZUMA-7(NCT03391466) and TRANSFORM(NCT03575351) trials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!